<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107872</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1321</org_study_id>
    <nct_id>NCT02107872</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
      study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and
      pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>visit 1 to day 183 (EOS)</time_frame>
    <description>Safety of REGN1500 will be assessed by physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations from visit 1 to day 183 [EOS (end of study)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>visit 1 to day 183</time_frame>
    <description>Serum concentration, amount of REGN1500 in the circulation, over time (visit 1 to day 183)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1500</intervention_name>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_label>dosing cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_label>dosing cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed informed consent

          -  Otherwise healthy men and women ages 18 to 65 years, inclusive

          -  Body mass index of 18.0 kg/m2to 38.0 kg/m2, inclusive

          -  Normal standard 12-lead ECG

          -  Willing to refrain from the consumption of alcohol for 24 hours prior to each study
             visit

          -  Willing to consistently maintain his/her usual diet for the duration of the study

          -  Willing to refrain from strenuous exercise for the duration of the trial

          -  Willing and able to comply with clinic visits and study-related procedures

          -  For sexually active men and women of childbearing potential, willingness to utilize
             adequate contraception and not become pregnant (or have their partner[s] become
             pregnant) during the full duration of the study.

        Exclusion Criteria:

          -  Any clinically significant abnormalities observed during the screening visit

          -  History of drug or alcohol abuse within 1 year of screening

          -  Receipt of another investigational drug or therapy within 30 days or at least 5
             half-lives (whichever is longer), of the investigational drug prior to the screening
             visit.

          -  Significant concomitant illness or history of significant illness such as cardiac,
             renal, neurological, endocrinological, metabolic or lymphatic disease, or any other
             illness or condition that may adversely affect the subjects participation in this
             study

          -  Known history of human immunodeficiency virus (HIV) antibody; and/or positive
             hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at the
             screening visit

          -  Hospitalization for any reason within 60 days of screening

          -  History or presence of malignancy within 5 years prior to the screening visit (other
             than successfully treated non-metastatic cutaneous squamous cell or basal cell
             carcinoma, and/or localized carcinoma in situ of the cervix

          -  Any medical or psychiatric condition which, in the opinion of the investigator, would
             place the subject at risk, interfere with participation in the study or interfere with
             the interpretation of the study results

          -  Any subject who is the investigator or any sub-investigator, research assistant,
             pharmacist, study coordinator, or other staff directly involved in the conduct of the
             protocol, or family member of staff involved in the conduct of the protocol

          -  Pregnant or breast-feeding women

        Note: The information listed above is not intended to contain all considerations relevant
        to a patient's potential participation in this clinical trial and not all inclusion/
        exclusion criteria are listed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

